Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 8/20 | 0.32 |
| ▸ | CNR1 | P21554 | 7/20 | 0.32 |
| ▸ | LNPEP | Q9UIQ6 | 2/20 | 0.31 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.31 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.31 |
| ▸ | RARA | P10276 | 1/20 | 0.31 |
| ▸ | RARB | P10826 | 1/20 | 0.31 |
| ▸ | PDE4A | P27815 | 1/20 | 0.30 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19854652 | 0.99 | CNR2 (0.33) | CNR2CNR1LNPEPITGB3ITGA2B | |
| SCHEMBL20407705 | 0.95 | CNR2 (0.31) | CNR2CNR1LNPEPITGB3ITGA2B | |
| SCHEMBL20322660 | 0.94 | — | — | |
| SCHEMBL20407707 | 0.94 | LNPEP (0.31) | LNPEPITGB3ITGA2B | |
| SCHEMBL20322883 | 0.94 | CNR1 (0.30) | CNR2CNR1 | |
| SCHEMBL20313561 | 0.93 | CYP2C9 (0.32) | PDE4APDE4D | |
| SCHEMBL19854668 | 0.91 | MEN1 (0.30) | — | |
| SCHEMBL19722539 | 0.89 | CNR2 (0.38) | CNR2CNR1LNPEPITGB3ITGA2B | |
| SCHEMBL19855537 | 0.89 | RARB (0.39) | CNR2CNR1ITGB3ITGA2BRARA | |
| SCHEMBL19855087 | 0.89 | PPARG (0.36) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3351525-A1 | POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY ELEMENT | JNC Corporation (JP) | 2018-07-25 | — | — | EP | disclosed |
| US-20180179443-A1 | POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-06-28 | — | — | US | disclosed |
| US-20180179443-A1 | POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180179443-A1 | POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | C1S, CCND1, C5 | CNR2 668/4885CNR1 229/4885LNPEP 3602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.